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SUMMARY 
Current pulmonary treatments against Pseudomonas aeruginosa infections in cystic fibrosis 
(CF) lung suffer from deactivation and immobilization of the drug in thick and viscous 
biofilm/mucus blend, along with the general antibiotic resistance.  
The present work suggests pulmonary antibiotic delivery with high load, capable of penetrating 
the tight mesh of biofilm/mucus as a solution to existing treatment bottlenecks. The potential 
use of nanoparticulate drug delivery systems to improve the treatment efficiency of lung 
infections in CF lungs is investigated. 
First chapter describes counter-ion complexes as a strategy to enhance drug load and 
demonstrates its applicability to different antibiotic classes, as well as counter-ions. The 
second chapter focuses on the drug delivery system development and its optimization via 
design-of-experiments approach. For the proof-of-concept studies, biodegradable and 
biocompatible poly (lactic-co-glycolic acid) was suggested and ciprofloxacin was used as 
model drug substance. MicroJet Reactor (MJR) technology, a precise preparation technique 
performed under controlled conditions, was employed. Effect of each process parameter was 
evaluated to ensure quality-by-design. Final chapter is dedicated to physico-chemical and in 
vitro characterization of the optimized nanoparticles.  
Overall, the new established approach offers counter-ion complex loaded PLGA NPs as 
promising pulmonary nano drug delivery system against P. aeruginosa infections in CF lung 
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ZUSAMMENFASSUNG 
Behandlungen von Pseudomonas aeruginosa Infektionen der Lunge von zystischer Fibrose 
(CF) Patienten, leiden unter Deaktivierung und Immobilisierung des Medikaments in dicken 
und viskosen Biofilm / Schleim Mischungen, zusammen mit der allgemeinen Antibiotika-
Resistenz. 
Die vorliegende Arbeit schlägt eine pulmonale Antibiotika Verabreichung mittels Nanopartikeln 
mit hoher Wirkstoffbeladung vor, die in der Lage sind, das enge Maschenwerk von Biofilm / 
Schleim zu durchdringen, als eine Lösung für bestehende Behandlungsengpässe. Die 
potenzielle Verwendung von nanopartikulären Drug Delivery-Systemen, zur Verbesserung der 
Behandlungseffizienz von Lungeninfektionen bei Patienten mit CF, wird untersucht. 
Das erste Kapitel beschreibt Gegenion-Komplexe als Strategie zur Verbesserung der 
Wirkstoffbeladung und zeigt ihre Anwendbarkeit auf verschiedene Antibiotika-Klassen sowie 
Gegenionen. Das zweite Kapitel konzentriert sich auf die Entwicklung der Drug Delivery-
Systeme sowie deren Optimierung durch einen Design-of-Experiments Ansatz. Für die 
Machbarkeitsstudien wurde das biologisch abbaubare und biokompatible Poly (lactid-co-
glycolid) eingesetzt und Ciprofloxacin als Modell-Wirksubstanz verwendet. Die Mikrojetreaktor 
(MJR) Technologie wurde dafür eingesetzt, da sie eine präzise Herstellung unter kontrollierten 
Bedingungen ermöglicht. Die Auswirkung jedes Prozessparameters wurde evaluiert, um 
quality-by-design sicherzustellen. Das abschließende Kapitel widmet sich der physikalisch-
chemischen und in vitro-Charakterisierung der optimierten Nanopartikel. 
Insgesamt bietet der neu etablierte Ansatz, von Gegenion-Komplex beladenen PLGA-
Nanopartikeln, vielversprechende pulmonale Nano-Drug Delivery-Systeme gegen P. 
aeruginosa-Infektionen in Lungen von CF-Patienten. 
 
 
  

OBJECTIVES 
1 
 
I. OBJECTIVES 
Recent analysis shows that there are already 1400 types of nanoparticles (NPs) available in 
the world market today1. Current developments in nanotechnologies applied to medicine 
(Nanomedicine) have shown that engineered drug delivery systems with the size order of 
nanometers are intriguing tools, which are capable of solving unmet problems in healthcare.  
 
Cystic fibrosis (CF) is a rare, genetic chronic 
disease, with its onset occurring in early 
childhood. The life-span of patients with CF is 
reported as only 30-40 years [1].  
Chronic pulmonary infections, among which 
Pseudomonas aeruginosa is known to be the 
major pathogen, are reported to be the main 
cause of mortality among CF patients [2]. Current 
available CF therapy targets the disease 
symptoms and not its causation; mainly due to six 
recognized classes of mutations of cystic fibrosis 
transmembrane regulator gene (CFTR), which 
result in an abnormal production of mucus in the lungs (Figure 1). In addition to airway 
clearance therapies, during the last decades, repeated courses of high doses of nebulized and 
inhaled antibiotics have been applied extensively for treatment of early infections as a 
preventive action against mucoidic bacteria [3-7]. However, once infection is established in the 
airways, it is almost impossible to eradicate it. The established biofilm anchors the bacteria to 
                                               
1 http://www.researchandmarkets.com/research/kv6mm5/nanotechnology 
Figure 1: image that summarises the 
overall impact of CFTR mutations, 
which ultimately influence 
the function or quantity of CFTR 
protein (Images available from 
http://www.cftr.info/about-cf/cftr-
mutations/the-six-classes-of-cftr-
defects/ Accessed in June 2017) 
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their environment, protects the bacteria and prevents drugs reaching minimum inhibition 
concentration at the site of action to kill bacteria [8]. 
Pulmonary drug delivery offers solutions to above mentioned problems, such as avoiding first 
pass effect, reduced systemic side effects, delivering higher doses at the site of action thus 
increased local concentration [9], higher bioavailability partially because of relatively low 
enzymatic activity [10], increasing patient compliance and being an non-invasive drug delivery 
method [11]. And may be the most important of all, for respiratory diseases such as CF, 
pulmonary drug delivery ensures local delivery.Under such disease conditions, a local nano 
drug delivery system capable of penetrating the thick mucus and biofilm, releasing antibiotic in 
a controlled manner at the site of action is intended for the treatment of chronic P. aeruginosa 
infections in CF lungs based on a systematic scientific rational. Main focus of this dissertation 
is the development and production of the nanoparticles with the microjet reactor technology to 
be later introduced into the final dry powder inhalation formulation with an adequate mass 
median aerodynamic diameter (MMAD) to ensure drug deposition at the upper airways, where 
the bacteria reside, as shown in Figure 2.  
 
 
Figure 2: Graphical depiction of the suggested pulmonary drug delivery system for the 
treatment of chronic P. aeruginosa infections in CF  
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In order to improve the effectiveness of the antibiotics, nanoparticulate dosage forms are to be 
used in this thesis. The main goal, therefore, is to encapsulate antibiotics with the aid of 
nanotechnology for the treatment of P. aeruginosa infection in patients with CF. These 
nanocarriers can be further formulated to be inhaled directly into the lungs. Nebulizers or 
powder inhalers suitable for this purpose are already established on the market in various 
forms which allow the production of aqueous or solid aerosol particles in the optimum range 
(MMAD approx. 1-5 μm) for a deposition in the peripheral lung. Nanoparticles can interfere 
with the pathophysiologically thickened mucus layer and the tailored nanoparticles in a favored 
size may enable penetration to the thick mucus/biofilm network. Therefore, particles should be 
engineered to possess particle size smaller than this 3-dimensional complex CF mucus/biofilm 
meshes, and to prevent adsorption only onto the biofilm and entrapment in the biofilm via 
surface properties. Thus, higher concentrations of the antibiotics to be used (e.g., gentamycin, 
tobramycin or ciprofloxacin) can be achieved for a longer period of time at the actual site of 
action.  
For preparation of nanoparticles with such complexity, conventional preparation techniques 
might suffer from serious disadvantages, such as lack of control on nanoparticle preparation 
and batch-to-batch reproducibility problem [12, 13]. Although the precipitation represents the 
universal and inexpensive method for the production of small particles, with the available 
precipitation methods, particles with pre-set size could not be produced reliably in a 
reproducible manner. 
Therefore, the microjet reactor technology offering 
advantages, such as continuous manufacturing under 
fully controlled conditions, to overcome the bottlenecks 
of conventional methods was employed for preparation 
of this highly sophisticated drug delivery system. This 
means a considerable advantage in terms of a 
controllable particle size, a particle size distribution as 
narrow as possible, as well as an easy scaling-up possibility of the process.  
 
Figure 3: A closer look into the 
microjet reactor 
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Microjet reactor with confined impinging jet principle, enables very high-quality of 
homogeneously distributed particle production. Combined with statistical experimental 
planning, efficient development of highly specialized, customized particles is realized. In 
general, microjet reactor produced nanoparticles possess narrow particle size distribution in 
comparison to traditional methods, since shorter mixing times (up to < 0.1 ms) and micro mixing 
can be achieved by microjet reactor. Thus, homogenous dissipation of the entire energy in 
micro volume is facilitated. Reaction times faster than crystal growth time result in smaller 
particle sizes and homogenous particle size distribution under controlled conditions. 
Additionally, in microjet reactor, with the high flow velocity, impinging jets leading to turbulence 
provide further efficient micro-mixing and shorter nanoparticle formation times. Thus, fast 
equilibrium establishment conditions and large surface to volume ratio are generated, and the 
need for additional stabilization is minimized. 
 
In order to be able to meet the requirements listed above, the overall project is divided into 
three sections: 
First section focuses on development of a strategy to encapsulate antibiotics in a suitable 
carrier at sufficient concentrations. An intensive literature survey was performed to understand 
the CF disease conditions, treatment bottlenecks and challenges, as well as innovative 
approaches that have been investigated by other researchers [14]. It was concluded that the 
NPs should possess surface properties that might prevent adsorption onto the biofilm surface 
and entrapment in the biofilm and avoid fast clearance. And a controlled release mechanism 
to ensure drug release at the site of action was preferred. All those expectations could have 
been realized by poly(lactic-co-glycolic) acid (PLGA), an FDA approved, biocompatible and 
biodegradable polymer. Considering the current therapy guidelines and clinical studies on-
going, fluoroquinolone antibiotic ciprofloxacin was assigned as model drug. 
Encapsulation of antibiotics showing pH dependent solubility characteristics along with limited 
organic solvent solubility was a challenge regardless of the applied preparation techniques. 
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The drug can neither be dissolved in a common organic solvent due to low solubility nor in pH-
adjusted aqueous solvents due to the in vitro degradation of the PLGA by acidic and alkaline 
environment, which is well-known to be accelerated under such conditions [15, 16]. Thus, drug 
loading was very low. To enhance drug load in nanocarriers, counter-ion complexes was 
developed and its applicability to different antibiotic classes, as well as counter-ions was 
demonstrated [17].  
The second chapter focuses on the drug delivery system development and its optimization via 
design-of-experiments approach. In addition to reaching the site of absorption and enhancing 
the deposition, especially in case of lung diseases like CF, where structural abnormalities are 
observed, particles should be engineered for an improved interaction. Considering these 
ultimate goals we can foresee that nanoparticles, owing to their small size, with custom made 
surfaces may pass the thick mucus layer easily through the gaps within the mesh structured 
biofilms and reach the bacteria without being trapped in the thick mucus and biofilm upon 
pulmonary drug delivery [14]. For the proof-of-concept studies, PLGA was employed and 
ciprofloxacin-SDS complex was used as model drug substance. Effect of each MJR process 
parameter was evaluated to ensure quality-by-design.  
Final chapter is dedicated to physico-chemical and in vitro characterization of the optimized 
nanoparticles. NPs` success also depends on their potential to reach the bacteria. Thus 
interaction with mucus, dissolution profile to sustain the local concentration at the site of action 
and release kinetics to understand the underlying physical and chemical phenomena were 
characterized. Additionally, stability have been evaluated to ensure sustainability of the 
developed particles. 
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II. SCIENTIFIC BACKGROUND 
Inhalable Antibiotic Nanoformulations for the Treatment of Pseudomonas aeruginosa 
Infection in Cystic Fibrosis 
 
 
 
 
  
Keywords: Antibiotic loaded nanoparticles, bacterial infection, nanoparticles, Pseudomonas 
aeruginosa, pulmonary nanoparticulate, drug delivery. 
 
Online available at: 
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ABSTRACT 
Cystic fibrosis (CF), a genetic lethal chronic disease, causes the body to produce abnormally 
thick and sticky mucus. As a consequence following bacterial infections threaten ten thousands 
of people around the world every year. Available tests enable early diagnosis of CF. 
Nevertheless, current treatments can only serve to improve patient’s quality of life. Despite the 
fact that life span of CF patients is dramatically increased with comprehensive treatments 
during the last decades, there is no ultimate prevention or cure for CF. Chronic respiratory 
infections are known to be the major cause of morbidity and mortality. Since the airways 
provide direct access to these bacteria, it is an attractive target for drug delivery against 
bacterial infections in CF lung. Current pulmonary treatments are, however, limited since 
reaching the site of action is highly inhibited by the biofilm, which establishes an efficient 
obstacle for drug diffusion. Recent developments in nanotechnology have led many 
researchers to study different types of nanoparticles and nanoformulations for pulmonary drug 
delivery in the scope of providing a solution to current treatment bottlenecks. This review 
focuses on the development of nanoparticulate antibiotic pulmonary drug delivery systems for 
the treatment of Pseudomonas aeruginosa infected CF lungs. 
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CHAPTER 1: COUNTER-ION COMPLEXES 
 
 
Keywords: Counter-ion complex, Enhanced encapsulation, Nanomedicine 
 
Online available at: 
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Chemical compounds studied in this article: Acetonitrile (PubChem CID: 6342); Ciprofloxacin 
(PubChem CID: 2764); Dimethyl sulfoxide (PubChem CID: 679); 1,2-Dipalmitoyl-sn-glycero-
3-phosphatidic acid, sodium salt (PubChem CID: 643979); Gentamicin (PubChem CID: 
3467); Pluronic® F68 (PubChem CID: 24751); Poly(DL-lactide-co-glycolide) (PubChem CID: 
71391); sodium dodecyl sulfate (PubChem CID: 3423265); Tobramycin (PubChem CID: 
36294)2 
  
                                               
2Abbreviations 
ACN, Acetonitrile; DMSO, Dimethyl sulfoxide; DPPA, 1,2-Dipalmitoyl-sn-glycero-3-phosphatidic 
acid, sodium salt; DSC, Differential scanning calorimetry; EE, Encapsulation efficiency; FTIR, Fourier 
transform infrared spectroscopy: HPLC, High pressure liquid chromatography; MJR, Microjet reactor; 
NP, Nanoparticle, PDI, Polydispersity index; PLGA, Poly(lactic-co-glycolic) acid; SDS, sodium 
dodecyl sulfate; XRD, X-Ray diffractometry.  
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ABSTRACT 
Enhanced drug loading is important prerequisite of nanomedicines, to reach administration 
dose while reducing the amount of excipient. Considering biocompatible and biodegradable 
polymers such as PLGA, pH dependent solubility characteristics along with limited organic 
solvent solubility of the drug hampers nanoparticle (NP) preparation. To improve loading of 
such molecules, a method based on using counter ions for complex formation is proposed. 
Formed complex alters the intrinsic solubility of active substance via electrostatic interaction 
without chemical modification. A proof-of-concept study was conducted with sodium dodecyl 
sulfate as counter-ion to fluoroquinolone antibiotic ciprofloxacin. Complex formation resulted 
in suppressed pH dependent solubility over pH 1.2 to 9.0 and an additional -80 fold increase 
in organic solubility was achieved. In consequence, NPs prepared by microjet reactor 
technology have shown enhanced drug loading efficiencies (- 78%) and drug loading of 14%. 
Moreover, the counter-ion concept was also demonstrated with another class of antibiotics, 
water soluble aminoglycosides gentamycin and tobramycin. In addition, the counter ion was 
substituted by degradable excipients such as phosphatidic acid derivatives. Successful 
implementation has proven the counter-ion concept to be a platform concept that can be 
successfully implemented for a variety of active substances and counter-ions to enhance 
drug loading in nanocarriers. 
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ABSTRACT 
Design of Experiments (DoE) is a powerful tool for systematic evaluation of process 
parameters` effect on nanoparticle (NP) quality with minimum number of experiments. DoE 
was employed for optimization of ciprofloxacin loaded PLGA NPs for pulmonary delivery 
against Pseudomonas aeruginosa infections in cystic fibrosis (CF) lungs. Since the biofilm 
produced by bacteria was shown to be a complicated 3D barrier with heterogeneous meshes 
ranging from 100 nm to 500 nm, nanoformulations small enough to travel through those 
channels were assigned as target quality. Nanoprecipitation was realized utilizing MicroJet 
Reactor (MJR) technology based on impinging jets principle. Effect of MJR parameters flow 
rate, temperature and gas pressure on particle size and PDI was investigated using Box-
Behnken design. The relationship between process parameters and particle quality was 
demonstrated by constructed fit functions (R2=0.9934 p < 0.0001 and R2=0.9983 p < 0.0001, 
for particle size and PDI, respectively). Prepared nanoformulations varied between 145.2 and 
979.8 nm with PDI ranging from 0.050 to 1.00 and showed encapsulation efficiencies > 65%. 
Response surface plots provided experimental data-based understanding of MJR parameters` 
effect, thus NP quality. Presented work enables ciprofloxacin loaded PLGA nanoparticle 
preparations with pre-defined quality to fulfill the requirements of local drug delivery under CF 
disease conditions. 
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ABSTRACT 
Current pulmonary treatments against Pseudomonas aeruginosa infections in cystic fibrosis 
(CF) lung suffer from deactivation of the drug and immobilization in thick and viscous 
biofilm/mucus blend, along with the general antibiotic resistance. Administration of 
nanoparticles (NPs) with high antibiotic load capable of penetrating the tight mesh of 
biofilm/mucus can be an advent to overcome the treatment bottlenecks. Biodegradable and 
biocompatible polymer nanoparticles efficiently loaded with ciprofloxacin complex offer a 
solution for emerging treatment strategies. NPs were prepared under controlled conditions by 
utilizing MicroJet Reactor (MJR) to yield a particle size of 190.4 ± 28.6 nm with 0.089 PDI. 
Encapsulation efficiency of the drug was 79% resulting in a loading of 14%. Release was 
determined to be controlled and medium-independent in PBS, PBS + 0.2% Tween 80 and 
simulated lung fluid. Cytotoxicity assays with Calu3 cells and CF bronchial epithelial cells 
(CFBE41o-) indicated that complex loaded PLGA NPs were non-toxic at concentrations 
>> MICcipro against lab strains of the bacteria. Antibacterial activity tests revealed enhanced 
activity when applied as nanoparticles. NPs’ colloidal stability in mucus was proven. Notably, 
a decrease in mucus turbidity was observed upon incubation with NPs. Herewith, ciprofloxacin 
complex loaded PLGA NPs are introduced as promising pulmonary nano drug delivery 
systems against P. aeruginosa infections in CF lung. 
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IV. CONCLUSION  
Chronic lung infections are reported to be the main cause of mortality among cystic fibrosis 
(CF) patients. During the last decades, in addition to airway clearance techniques, high doses 
of nebulized and inhaled antibiotics have been applied extensively for treatment of early 
infections as a preventive action against the mucoidic bacteria. However, once the infection is 
established in the airways, it is almost impossible to eradicate it. CF onset occurs in early 
childhood and the life-span of patients with CF is reported as only 30-40 years.  
The aim of the study was the development of a drug delivery system for the treatment of chronic 
P. aeruginosa infections in CF based on a systematic scientific rational. Under such disease 
conditions, a local nanoparticle drug delivery system which is capable of penetrating the thick 
mucus and biofilm, releasing the antibiotic in a controlled manner at the site of action was 
considered as a scientific basis for the design of a (nano-)particulate drug delivery system for 
antibiotic drugs.  
Main focus of this dissertation was the development and production of the necessary 
nanoparticles with the microjet reactor technology to be later introduced into a final drug 
delivery system. The tailor made nanoparticles in a favored size might play a decisive role for 
the effect at certain target sites in the body, since they may enable penetration to the thick 
mucus/biofilm network. 
In this thesis, a novel approach, counter-ion method, was developed for enhanced drug loading 
in nanocarriers by altering the solubility of the small molecules, and efficiency of the approach 
was proven for different classes of antibiotics and counter-ions. Relying on that approach, 
antibiotic-complex loaded poly (lactic-co-glycolic acid) (PLGA) nanoparticles were prepared by 
utilizing microjet reactor technology, which allows full control over the manufacturing process. 
Optimization of those nanoparticles for  
i. particle size to minimize size exclusion in meshes of cystic fibrosis lung mucus/biofilm 
blend,  
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ii. narrow PDI to ensure homogeneity 
were achieved via design of experiments by optimization the process parameters, whereas, 
iii. mobility in mucus/biofilm blend to deliver the drug to the site of action 
iv. high drug load and controlled release kinetics to ensure sustained antibiotic 
concentration at the site of action  
were achieved by screening different formulation components and compositions. Finally, 
performance of optimized antibiotic-complex loaded PLGA nanoparticles were proven in 
in - vivo simulating environment, as well as horse lung mucus.  
 
In the first section, a strategy to enhance the drug load in nanocarriers was aimed, since early 
development stages revealed that drug loading into PLGA nanocarrier was hampered, when 
the drug shows pH dependent solubility characteristics. Neither use of a common organic 
solvent nor use of buffered solutions were possible due to solubility and stability limitations of 
both ciprofloxacin and PLGA. In order to overcome those bottlenecks, counter-ion method that 
relies on electrostatic interaction between oppositely charged small molecule and counter-ion 
was suggested as solubility modulator to suppress the pH dependent solubility characteristics, 
thus enhance the drug loading. For the proof-of-concept studies, ciprofloxacin-sodium dodecyl 
sulfate complex was prepared and fully characterized. Complex formation was confirmed via 
HPLC, spectral and thermal analysis, as well as X-Ray diffraction. In addition to suppressing 
pH depending solubility of ciprofloxacin, solubility studies revealed a very pronounced effect 
on organic solubility and led to 80-fold increase. By this way, a common solvent for both 
ciprofloxacin and the nanocarrier could be identified without a negative effect on PLGA stability. 
Occurrence of the complex formation without a chemical modification was proven via similarity 
analysis of the ciprofloxacin and ciprofloxacin-complex UV-spectra after dissolving in aqueous 
solutions of wide pH range, proving dissociation of complex to its components upon dissolving. 
This finding was confirmed by HPLC purity analysis, where no partition difference was 
observed (same retention time for both complex and ciprofloxacin) and 3D-comparison (in 
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dimensions of time-wavelength-absorbance) of the spectra was indicating only ciprofloxacin 
detection in aqueous environment. Additionally, antibacterial activity of ciprofloxacin complex 
against lab strains of Pseudomonas aeruginosa was significantly enhanced in comparison to 
free ciprofloxacin. 
Applicability of the counter-ion complexes to different antibiotic classes, as well as counter-
ions were demonstrated in two case studies. In the first case study, ciprofloxacin complex was 
prepared by another counter ion, dipalmitoyl phosphatidic acid (DPPA), a precursor of de novo 
synthesized lung surfactant phosphatidyl choline. It was shown that ciprofloxacin-DPPA 
complex could be formed by slight modification of the counter-ion approach, allowing 
solubilization of counter-ion DPPA in an organic solvent. Ciprofloxacin-DPPA complex 
formation was proven via X-Ray diffraction, thermal and spectral analysis and solubility of the 
formed complex was characterized in organic solvents. Results showed altered and enhanced 
organic solvent solubility in accordance with the output of original approach. Antibacterial 
activity of both ciprofloxacin complexes gathered using SDS and DPPA against lab strains of 
P. aeruginosa were significantly enhanced in comparison to free ciprofloxacin. In the second 
case study, tobramycin and gentamicin, antibiotics belonging to aminoglycoside classes, 
complexes were prepared with sodium dodecyl sulfate as counter-ion without any modification 
of the original approach and successful complex formation was proven via thermal analysis. 
At the end of first section it was proven that counter-ion complexes enabled altered solubility 
characteristics without chemical or activity modification and are applicable to a variety of 
substances/antibiotic classes and counter-ions. Considering that the unlimited combinations 
of substances with a variety of counter-ion complexes, it was concluded that this approach 
was not only beneficial for pharma industry but also offering a great potential for nutraceuticals 
and cosmetics. It also can be employed for tailoring the complexes depending on the 
administration route (e.g. complex with deoxycholic acid for oral administration etc.).  
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The second aim was the drug delivery system development and its optimization. Quality target 
attributes of the particles were defined as; 
i. particle size; small enough to penetrate through the thick mucus and bacterial biofilm 
blend, the biobarrier of CF, without being immobilized 
ii. PDI; narrow particle size distributions to ensure that the whole nanoparticle population 
has uniform sizes 
iii. drug load; high enough to reach the application dose, in other words, therapeutic 
concentration range at the site of action 
iv. surface stabilization; appropriate stabilizer properties to minimize undesired 
interactions with the cystic fibrosis biobarrier, hence facilitate penetration  
Microjet reactor technology, a precise preparation technique performed under controlled 
conditions, was employed for continuous particle production. Microjet reactor offers unlimited 
scale-up since same process parameters can be used for both lab scale and industrial scale 
manufacturing of nanoparticles. Microjet reactor enables control over the whole process 
parameters and environment, and turbulent-like micromixing in a gas filled chamber caused 
by impinging jets provides efficient production for high quality nanoparticles. Nanoparticle 
quality can be theoretically defined as a function of parameters that govern the whole process. 
Thus, effect of each process parameter (flow rate, temperature, applied gas pressure) was 
evaluated to ensure quality-by-design via design of experiments. Particle size and PDI were 
assigned as target quality prerequisites to facilitate mobility in CF lung local microenvironment. 
Model fit function, correlating the process parameters and the particle size and PDI, were 
constructed. Evaluation of the response surface graphs elucidated that all process parameters 
significantly influenced the particle size and PDI. When two jet streams imping, a disc is formed 
at the impinging point, where micromixing is achieved. It was concluded that if the mixing time 
is faster than the nucleation induction time, further improvement in the mixing efficiency via 
higher flow rates wouldn’t affect the particle size and PDI. It was shown that the hydro-
dynamics in the impingement disc, where too high flow rates were employed, led to non-
optimal mixing conditions, resulted in a reduced residence time in the microjet reactor, thus 
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uncontrolled nucleation and eventually higher particle sizes. Temperature was also shown to 
be significantly affecting the nanoparticle quality and to be within an appropriate range for the 
exothermic nanoprecipitation process. An increase in temperature caused decrease in particle 
size due to reduced viscosity of both phases, contributing positively to mixing efficiency and 
the faster longitudinal movements of both solvent and solute at the mixing interface. On the 
other hand, an increase in applied gas pressure resulted in higher particle sizes and PDI. This 
observation was attributed to the distorted impinging disc upon application of high pressures 
of gas, thus uncontrolled nucleation and particle size growth. The process parameters yielding 
nanoparticle preparation with the desired quality attributes were extracted from the fit functions. 
The ability of the model fit function to predict those quality attributes was validated with normal 
probability plot. Successful validation of the constructed fit functions enabled defining the 
microjet reactor parameters within the predefined design space to fine-tune quality of 
nanoparticles. 
 
The final aim was physico-chemical and in-vitro characterization of the optimized nanoparticles 
for prediction of their in-vivo performance. Since encapsulation was designed for protecting 
the antibiotic from hostile microenvironment in CF lungs leading to deactivation before it can 
reach the bacteria, mucus interaction of the particles was evaluated by employing horse lung 
mucus. Horse lung mucus was chosen as an alternative model, due to very limited access to 
human lung mucus. Spectral analysis showed that upon interaction with the nanoparticles the 
mucus network was undergoing a change, optical density of the mucus network was 
decreasing immediately after mixing and the dense structure was becoming leakier. And this 
effect was concentration dependent: as the nanoparticle concentration in the mucus increased 
the disaggregation grade of the mucus increased, as well. These findings were supported by 
cryo-SEM analysis: mucus incubated with NP showed structural differences in comparison to 
control mucus. However, it is worth mentioning that sample preparations and sample handling 
in cryo-SEM requires very intensive method development and due to limited availability of 
mucus, it was not possible to evaluate the effect in detail. Particle size and zeta potential of 
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the nanoparticles did not show any significant change after mucus incubation without an 
indication of agglomeration. Particles were shown to be stable in mucus environment. 
Evaluation of the nanoparticle-mucus interaction with those two in-vitro methods suggested 
the mobility of ciprofloxacin complex loaded PLGA nanoparticles in mucus and capability of 
penetrating through the mucus owing to their surface properties, size and ZETA potential. If 
the disaggregation of the network is caused by the nanoparticles repelling the mucus 
components due to surface properties or due to reduced number of obstacles in the penetration 
path as a result of corona effect is worth investigating, since this might provide an important 
know-how for next generations of drug delivery systems developed for treatment of bacterial 
infections in CF lungs. Finally, the antibacterial activity of complex loaded PLGA nanoparticles 
were tested against lab strains of P. aeruginosa. It was found out that the ciprofloxacin complex 
loaded PLGA nanoparticles were more effective against bacteria than the free ciprofloxacin 
and this enhanced antibacterial activity was not related to any synergic effect from other 
nanoparticle components probably due to better penetration of nanoparticles through agar 
plates. Furthermore, a controlled drug release reaching to maximum 80% in 8 hours was 
shown in in-vivo simulating media with dissolution studies and it was found out that the release 
kinetics were driven by the polymer, indicating successful encapsulation of the active 
substance in polymer preventing burst effect. 
 
In this thesis, a local nano drug delivery system capable of penetrating the thick mucus and 
biofilm, showing stability in this microenvironment and releasing antibiotic in a controlled 
manner at the site of action for treatment of cystic fibrosis bacterial lung infections was 
presented. High drug loading of the nanoparticles was achieved by innovative counter-ion 
method, which enabled drug loading up to 14%. On the other hand, it is known that antibiotics 
are delivered at high dosis is due to low drug concentration at the site of action which is limited 
by the disease condition. Considering the enhanced antibacterial activity of the complex and 
complex loaded PLGA nanoparticles, taken together with the ability of the particles to carry the 
complete drug load directly to the infection area might reduce the application dosis. However, 
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this is an expectation that requires further formulation of nanoparticles for possessing right 
mass median aerodynamic diameter to ensure deposition at the upper airways, where the 
bacteria reside, in-vivo profiling and testing. Regardless of how high drug loading was 
achieved, early studies on formulation of those nanoparticles via lyophilization with mannitol 
was not very promising due to very low antibiotic loaded PLGA nanoparticle: mannitol ratio. 
Mannitol was assigned as formulation excipient since it offers a very broad range of 
improvements to the formulation as an excipient. It is already approved as mucolytic and an 
integrated part of CF therapy in the form of capsules for inhalation. Additionally, it enhances 
penetration and uptake [1], and serves as C-source to mucoid bacteria at depleted nutrition 
conditions, thus eventually might be a trigger for favoring the conditions for planktonic bacteria 
[2]. Once optimum formulation conditions are realized, pulmonary administration of 
nanoformulations with higher drug loading is a promising tool for treatment of infections. 
 
Thanks to translational research and clinicians actively working on advance in the treatment, 
today life span of a CF patient is dramatically increased over the last decades, however there 
is no cure to the disease. Considering that the pulmonary infections are the major cause of 
morbidity in CF, a very intensive and personalized care is required to keep the airways clear 
and prevent chronic infections. Pulmonary nano antibiotic delivery systems, as the one 
developed and presented in this thesis, with high load, capable of penetrating thick mucus and 
sustaining the local concentrations may offer many advantages to CF bacterial infection 
treatment, thus increase life quality of the patients and might even prolong the life span.  
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